SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVictrex Regulatory News (VCT)

Share Price Information for Victrex (VCT)

Share Price is delayed by 15 minutes
Get Live Data
620.00    9.00 (1.47%)
Bid:
621.00
Ask:
623.00
Spread: 2.00 (0.322%)
Market Cap: £540.17m
VCT Live PriceLast checked at - London Stock Exchange

Intraday Victrex Share Chart

Trading Statement

8 Oct 2013 07:00

RNS Number : 9350P
Victrex PLC
08 October 2013
 



 

 

8 October 2013

Victrex plc - Year End Trading Statement

Victrex plc ('Victrex'), an innovative world leader in high performance polymers, today releases its year end trading statement, ahead of its 2013 preliminary results which will be announced on Tuesday 10 December 2013.

Full year sales volume was slightly ahead of last year at 2,920 tonnes (FY 2012: 2,904 tonnes) following a robust second half performance, with sales volume approximately 10% ahead of the first half year. Group sales volume of 1,528 tonnes for the second half was in line with the strong prior year performance (H2 2012: 1,527 tonnes), with good progress across our industrial and transport markets, offset by lower sales in the electronics market following the non-recurrence of last year's strong product launch related sales into consumer electronics.

In our Invibio Biomaterial Solutions business, full year revenue was slightly ahead of the prior year at £50.8m (FY 2012: £50.5m). This reflects steady improvement in sales to the Spine market during the second half year, with revenue 10% ahead of the first half, as inventory levels in the industry appear to have stabilised. Second half revenue in Invibio was also ahead of the prior year at £26.6m (H2 2012: £25.0m). Outside of the Spine market, we continue to see steady progress in our emerging market opportunities.

Outlook

Looking ahead to our new financial year, whilst we remain mindful of the wider economic environment, our order book for October is reassuring. Victrex remains confident in the diverse and multiple growth opportunities that are being developed across the business. Our investment in additional capacity, which is a key enabler to support and deliver our future growth programmes, remains on plan and on budget, with construction progressing well.

Victrex will host an Investor Day, 'Spotlight on Growth', in London this Thursday, 10 October 2013, with its Executive Management Team, including presentations by Tim Cooper, Managing Director of VPS, and Martin Court, Managing Director of Invibio, covering the scale of Victrex's Group wide growth programmes. No new trading or financial information will be disclosed during the Investor Day. 

 

Enquiries:

Victrex plc:

Andrew Hanson, Head of Investor Relations 01253 898121

Steve Barrow, Group Finance Director 01253 897700

 

MHP Communications:

Nick Denton/Barnaby Fry/James White 0203 128 8100

 

Investor and analyst conference call:

A conference call for Investors and Analysts will be held today, Tuesday 8 October, 09.00am. For further details please contact Ben Griffiths at MHP Communications on 0203 128 8100.

 

About Victrex:

Victrex is an innovative world leader in high performance polymers. Every day, millions of people rely on products or applications which contain our materials, from smartphones, aeroplanes and cars to oil & gas operations and medical devices. With over 30 years' experience, we are investing in technology leadership to deliver new solutions to our customers and our markets. Find out more at www.victrexplc.com

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTUGGWAUUPWGQM
Date   Source Headline
4th Jan 20121:38 pmRNSAnnual Information Update
4th Jan 201211:35 amRNSAnnual Financial Report
3rd Jan 201211:23 amRNSHolding(s) in Company
30th Dec 201112:00 pmRNSTotal Voting Rights
19th Dec 201112:00 pmRNSDirector/PDMR Shareholding
13th Dec 20113:43 pmRNSDirector/PDMR Shareholding
6th Dec 20117:00 amRNSFinal Results
1st Dec 201111:24 amRNSBlocklisting Interim Review
30th Nov 201111:48 amRNSTotal Voting Rights
17th Nov 201111:43 amRNSDirector/PDMR Shareholding
2nd Nov 20114:22 pmRNSHolding(s) in Company
31st Oct 20111:52 pmRNSTotal Voting Rights
19th Oct 20111:45 pmRNSDirector/PDMR Shareholding
6th Oct 20113:27 pmRNSHolding(s) in Company
6th Oct 20117:02 amRNSDirectorate Change
6th Oct 20117:00 amRNSYear End Trading Update
30th Sep 20112:14 pmRNSTotal Voting Rights
19th Sep 20114:22 pmRNSDirector/PDMR Shareholding
6th Sep 20112:52 pmRNSHolding(s) in Company
31st Aug 20113:38 pmRNSTotal Voting Rights
17th Aug 20113:26 pmRNSDirector/PDMR Shareholding
10th Aug 201110:48 amRNSHolding(s) in Company
4th Aug 20117:00 amRNSInterim Management Statement
29th Jul 20113:52 pmRNSTotal Voting Rights
29th Jul 20112:05 pmRNSHolding(s) in Company
19th Jul 20113:59 pmRNSHolding(s) in Company
19th Jul 20111:40 pmRNSDirector/PDMR Shareholding
4th Jul 20114:09 pmRNSHolding(s) in Company
1st Jul 20111:23 pmRNSTotal Voting Rights Replacement
30th Jun 20113:38 pmRNSDirector/PDMR Shareholding
27th Jun 20111:47 pmRNSHolding(s) in Company
17th Jun 20112:21 pmRNSDirector/PDMR Shareholding
8th Jun 20113:55 pmRNSDirector/PDMR Shareholding
1st Jun 201111:07 amRNSBlocklisting Interim Review
1st Jun 201111:01 amRNSTotal Voting Rights
24th May 20117:00 amRNSHalf Yearly Report
18th May 20112:20 pmRNSDirector/PDMR Shareholding
6th May 20112:53 pmRNSHolding(s) in Company
5th May 20114:22 pmRNSHolding(s) in Company
4th May 20113:00 pmRNSTotal Voting Rights
4th May 20112:51 pmRNSHolding(s) in Company
19th Apr 20112:44 pmRNSDirector/PDMR Shareholding
7th Apr 20117:00 amRNSTrading Update
1st Apr 201111:00 amRNSTotal Voting Rights
25th Mar 20111:59 pmRNSDirector Declaration
17th Mar 20112:44 pmRNSDirector/PDMR Shareholding
14th Mar 201112:30 pmRNSHolding(s) in Company
2nd Mar 201110:53 amRNSTotal Voting Rights
17th Feb 20112:36 pmRNSDirector/PDMR Shareholding
9th Feb 201110:21 amRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.